Cargando…

Gene expression profiling of CD34(+) cells from patients with myeloproliferative neoplasms

Myeloproliferative neoplasms (MPN) are clonal disorders characterized by the increased proliferation of hematopoietic stem cell precursors and mature blood cells. Mutations of Janus kinase 2 (JAK2), Calreticulin (CALR) and MPL (myeloproliferative leukemia virus) are key driver mutations in MPN. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Mugdha, Bhavani, Chandra, Suresh, Srinag Bangalore, Paul, John, Yadav, Lokendra, Ross, Cecil, Srivastava, Sweta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816297/
https://www.ncbi.nlm.nih.gov/pubmed/33574943
http://dx.doi.org/10.3892/ol.2021.12465
_version_ 1783638414666498048
author Sharma, Mugdha
Bhavani, Chandra
Suresh, Srinag Bangalore
Paul, John
Yadav, Lokendra
Ross, Cecil
Srivastava, Sweta
author_facet Sharma, Mugdha
Bhavani, Chandra
Suresh, Srinag Bangalore
Paul, John
Yadav, Lokendra
Ross, Cecil
Srivastava, Sweta
author_sort Sharma, Mugdha
collection PubMed
description Myeloproliferative neoplasms (MPN) are clonal disorders characterized by the increased proliferation of hematopoietic stem cell precursors and mature blood cells. Mutations of Janus kinase 2 (JAK2), Calreticulin (CALR) and MPL (myeloproliferative leukemia virus) are key driver mutations in MPN. However, the molecular profile of triple negative MPN has been a subject of ambiguity over the past few years. Mutations of, methylcytosine dioxygenase TET2, polycomb group protein ASXL1 and histone-lysine N-methyltransferase EZH2 genes have accounted for certain subsets of triple negative MPNs but the driving cause for majority of cases is still unexplored. The present study performed a microarray-based transcriptomic profile analysis of bone marrow-derived CD34(+) cells from seven MPN samples. A total of 21,448 gene signatures were obtained, which were further filtered into 472 upregulated and 202 downregulated genes. Gene ontology and protein-protein interaction (PPI) network analysis highlighted an upregulation of genes involved in cell cycle and chromatin modification in JAK2V617F negative vs. positive MPN samples. Out of the upregulated genes, seven were associated with the hematopoietic stem cell signature, while forty-seven were associated with the embryonic stem cell signature. The majority of the genes identified were under the control of NANOG and E2F4 transcription factors. The PPI network indicated a strong interaction between chromatin modifiers and cell cycle genes, such as histone-lysine N-methyltransferase SUV39H1, SWI/SNF complex subunit SMARCC2, SMARCE2, chromatin remodeling complex subunit SS18, tubulin β (TUBB) and cyclin dependent kinase CDK1. Among the upregulated epigenetic markers, there was a ~10-fold increase in MYB expression in JAK2V617F negative samples. A significant increase in total CD34 counts in JAK2V617F negative vs. positive samples (P<0.05) was also observed. Overall, the present data showed a distinct pattern of expression in JAK2V617F negative vs. positive samples with upregulated genes involved in epigenetic modification.
format Online
Article
Text
id pubmed-7816297
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-78162972021-02-10 Gene expression profiling of CD34(+) cells from patients with myeloproliferative neoplasms Sharma, Mugdha Bhavani, Chandra Suresh, Srinag Bangalore Paul, John Yadav, Lokendra Ross, Cecil Srivastava, Sweta Oncol Lett Articles Myeloproliferative neoplasms (MPN) are clonal disorders characterized by the increased proliferation of hematopoietic stem cell precursors and mature blood cells. Mutations of Janus kinase 2 (JAK2), Calreticulin (CALR) and MPL (myeloproliferative leukemia virus) are key driver mutations in MPN. However, the molecular profile of triple negative MPN has been a subject of ambiguity over the past few years. Mutations of, methylcytosine dioxygenase TET2, polycomb group protein ASXL1 and histone-lysine N-methyltransferase EZH2 genes have accounted for certain subsets of triple negative MPNs but the driving cause for majority of cases is still unexplored. The present study performed a microarray-based transcriptomic profile analysis of bone marrow-derived CD34(+) cells from seven MPN samples. A total of 21,448 gene signatures were obtained, which were further filtered into 472 upregulated and 202 downregulated genes. Gene ontology and protein-protein interaction (PPI) network analysis highlighted an upregulation of genes involved in cell cycle and chromatin modification in JAK2V617F negative vs. positive MPN samples. Out of the upregulated genes, seven were associated with the hematopoietic stem cell signature, while forty-seven were associated with the embryonic stem cell signature. The majority of the genes identified were under the control of NANOG and E2F4 transcription factors. The PPI network indicated a strong interaction between chromatin modifiers and cell cycle genes, such as histone-lysine N-methyltransferase SUV39H1, SWI/SNF complex subunit SMARCC2, SMARCE2, chromatin remodeling complex subunit SS18, tubulin β (TUBB) and cyclin dependent kinase CDK1. Among the upregulated epigenetic markers, there was a ~10-fold increase in MYB expression in JAK2V617F negative samples. A significant increase in total CD34 counts in JAK2V617F negative vs. positive samples (P<0.05) was also observed. Overall, the present data showed a distinct pattern of expression in JAK2V617F negative vs. positive samples with upregulated genes involved in epigenetic modification. D.A. Spandidos 2021-03 2021-01-12 /pmc/articles/PMC7816297/ /pubmed/33574943 http://dx.doi.org/10.3892/ol.2021.12465 Text en Copyright: © Sharma et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Sharma, Mugdha
Bhavani, Chandra
Suresh, Srinag Bangalore
Paul, John
Yadav, Lokendra
Ross, Cecil
Srivastava, Sweta
Gene expression profiling of CD34(+) cells from patients with myeloproliferative neoplasms
title Gene expression profiling of CD34(+) cells from patients with myeloproliferative neoplasms
title_full Gene expression profiling of CD34(+) cells from patients with myeloproliferative neoplasms
title_fullStr Gene expression profiling of CD34(+) cells from patients with myeloproliferative neoplasms
title_full_unstemmed Gene expression profiling of CD34(+) cells from patients with myeloproliferative neoplasms
title_short Gene expression profiling of CD34(+) cells from patients with myeloproliferative neoplasms
title_sort gene expression profiling of cd34(+) cells from patients with myeloproliferative neoplasms
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816297/
https://www.ncbi.nlm.nih.gov/pubmed/33574943
http://dx.doi.org/10.3892/ol.2021.12465
work_keys_str_mv AT sharmamugdha geneexpressionprofilingofcd34cellsfrompatientswithmyeloproliferativeneoplasms
AT bhavanichandra geneexpressionprofilingofcd34cellsfrompatientswithmyeloproliferativeneoplasms
AT sureshsrinagbangalore geneexpressionprofilingofcd34cellsfrompatientswithmyeloproliferativeneoplasms
AT pauljohn geneexpressionprofilingofcd34cellsfrompatientswithmyeloproliferativeneoplasms
AT yadavlokendra geneexpressionprofilingofcd34cellsfrompatientswithmyeloproliferativeneoplasms
AT rosscecil geneexpressionprofilingofcd34cellsfrompatientswithmyeloproliferativeneoplasms
AT srivastavasweta geneexpressionprofilingofcd34cellsfrompatientswithmyeloproliferativeneoplasms